BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced today that it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market closes. The company will host a conference call and webcast at 4:30 PM ET on the same day to provide an overview of the quarter's performance and growth initiatives.
The webcast will feature management's discussion of financial results and business developments. Interested parties can register for the event here. The conference call can be accessed by dialing (800) 715-9871 (North America toll-free) or +1 (646) 307-1963 (international), using conference ID 9695874.
BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, which are designed to preserve the natural properties of tissues for clinical use. Its products are utilized across various medical specialties, and the company maintains a growing portfolio and expanding clinical research initiatives.
The announcement comes as BioStem continues to expand its national commercial footprint. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™.
Investors and stakeholders can follow the latest developments by signing up for the company's email distribution list here or by following BioStem on X and LinkedIn. Additional updates are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
The Q1 2026 results and conference call will provide insights into BioStem's financial health and strategic direction, offering valuable information for leaders in the business and technology sectors tracking advancements in regenerative medicine.
